Overview

• The 8 mg per injection regimen is set as the second active dose for Phase 2b, with 20 injections totaling 160 mg per patient.
• Eupraxia plans to increase Phase 2b enrollment from about 60 to at least 120 participants, targeting a minimum of 40 patients per dose group.
• Patients in Cohort 9 achieved rapid clinical remission by the Straumann Dysphagia Index with the largest EoEHSS gains and eosinophil reductions reported to date.
• Safety findings show zero serious adverse events and zero cases of candidiasis across all treated patients, including those at the 8 mg dose.
• The company expects additional Phase 1b/2a data in Q4 2025, continues Phase 2b recruitment with a 120 mg first dose, targets top-line Phase 2b results in Q3 2026, and intends to launch an additional GI indication study in H1 2026.